Genedx Holdings CORP Form 4 insider transactions

GeneDx Holdings Corp.'s CFO, Kevin Feeley, sold 388 shares of Class A Common Stock to cover tax withholding obligations following the vesting of restricted stock units.

Keith A. Meister and Corvex Management LP amended a Form 4 to correct the reported beneficial ownership of GeneDx Holdings Corp. Class A Common Stock.

GeneDx Holdings Corp. CEO Katherine Stueland sold 12,858 shares of Class A Common Stock for approximately $1.4 million under a pre-arranged 10b5-1 trading plan.

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, exercised stock options and sold a significant number of Class A Common Stock shares pursuant to a pre-arranged 10b5-1 trading plan.

GeneDx Holdings Corp. Director Thomas Fuchs received a grant of 3,438 Restricted Stock Units, aligning his interests with shareholders.

GeneDx Holdings Corp.'s CFO, Kevin Feeley, filed an amended Form 4 to correct a typographical error regarding the acquisition of 7,197 Class A Common Stock shares from RSU vesting.

GeneDx Holdings Corp.'s CFO, Kevin Feeley, reported the acquisition of shares from RSU vesting and a subsequent sale to cover tax withholding obligations.

GeneDx Holdings Corp. CEO Katherine Stueland sold 10,501 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

GeneDx Holdings Corp. CEO Katherine Stueland sold shares to cover tax withholding obligations related to RSU vesting, not as a discretionary transaction.

GeneDx Holdings Corp.'s CFO, Kevin Feeley, sold a portion of Class A Common Stock to cover tax obligations related to RSU vesting, while increasing overall RSU beneficial ownership.

GeneDx Holdings Corp.'s CFO, Kevin Feeley, sold 378 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

GeneDx Holdings Corp. Director Jason Ryan sold 39,222 shares of Class A Common Stock on August 27, 2025, through a pre-arranged 10b5-1 plan.

Casdin Capital and related entities, including Director Eli Casdin, reported the sale of 500,000 shares of GeneDx Holdings Corp. Class A Common Stock, with a transaction date of August 22, 2025.

GeneDx Holdings Corp. Director Eli Casdin filed an amended Form 4 to correct clerical errors in previous beneficial ownership reports.

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax withholding obligations.

GeneDx Holdings Corp. CEO Katherine Stueland sold 2,154 shares of Class A Common Stock at $105.31 per share to cover tax withholding obligations related to the vesting of restricted stock units.

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, exercised stock options and subsequently sold a portion of his Class A Common Stock shares on July 9, 2025, as part of a pre-established Rule 10b5-1 trading plan.

GeneDx Holdings Corp. CEO Katherine Stueland sold 3,220 shares of Class A Common Stock for $93 per share on July 9, 2025, as part of a pre-arranged 10b5-1 trading plan.

GeneDx Holdings Corp. CEO Katherine Stueland sold a total of 9,657 shares of Class A Common Stock on July 1, 2025, through a pre-arranged Rule 10b5-1 trading plan.

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, has filed a Form 4 indicating planned sales of Class A Common Stock totaling 1,344 shares under a Rule 10b5-1 trading plan, effective July 1, 2025.

Eli Casdin, a Director and 10% Owner of GeneDx Holdings Corp., reported the acquisition of Class A Common Stock through RSU settlement and new RSU grants.

Keith A. Meister, a Director and 10% owner of GeneDx Holdings Corp., has filed a Form 4 detailing a substantial disposition of indirectly held shares alongside routine RSU grants and conversions, all planned for June 18, 2025.

GeneDx Holdings Corp. Director Jason Ryan has filed a Form 4 detailing the acquisition of new Restricted Stock Units and the conversion of existing RSUs into Class A Common Stock.

GeneDx Holdings Corp. Director Emily M. Leproust reported the vesting and conversion of 12,924 Restricted Stock Units into Class A Common Stock, alongside the acquisition of 3,576 new RSUs.

GeneDx Holdings Corp. Director Richard C. Pfenniger Jr. reported the conversion of 12,924 restricted stock units into Class A Common Stock and the acquisition of 3,576 new restricted stock units.

GeneDx Holdings Corp. Director Joshua Ruch reported the acquisition of Class A Common Stock through RSU conversion and a new RSU grant, increasing his direct and indirect beneficial ownership.

GeneDx Holdings Corp.'s CEO and Director, Katherine Stueland, reported the vesting of 18,750 restricted stock units and a subsequent sale of 10,501 shares to cover tax withholding obligations.

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, reported the acquisition of shares from restricted stock unit vesting and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, reported the acquisition of shares from restricted stock unit vesting and a subsequent 'sell to cover' transaction to satisfy tax obligations.

GeneDx Holdings Corp. CEO Katherine Stueland reported the acquisition of 6,547 shares from restricted stock unit vesting and the subsequent sale of 3,639 shares to cover tax obligations.